REVIEW article
Front. Pharmacol.
Sec. Drugs Outcomes Research and Policies
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1656557
Impact of Pharmacist-Interpreted pt-qPCR Technology on Antimicrobial Use and Clinical Outcomes in Patients with Lower Respiratory Tract Infections: A Retrospective Cohort Study
Provisionally accepted
- 1The First hospital of Hebei Medical University, Shijiazhuang, China
- 2Hebei Medical University School of Basic Medicine, Shijiazhuang, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: Lower respiratory tract infections (LRTIs) are a leading cause of morbidity and mortality worldwide and contribute to excessive empirical antibiotic use due to diagnostic delays. Rapid and accurate pathogen identification is essential for guiding targeted antimicrobial therapy and improving drug outcomes.Aim: This study aimed to evaluate the impact of pathogen-targeted quick multiplex PCR (pt-qPCR) compared to conventional microbiological testing on antimicrobial use and clinical outcomes in hospitalized patients with LRTIs.In this retrospective cohort study conducted at a tertiary hospital in China (March 2023-March 2024), patients with LRTIs were assigned to either a conventional testing group or a pt-qPCR group.Outcomes included pathogen detection rate, length of hospital stay (LOS), antimicrobial days of therapy (DOT), antimicrobial duration before and after testing, time to targeted therapy, mortality, and ICU transfer rate.Results: A total of 220 patients were enrolled (conventional: n=112; pt-qPCR: n=108). Baseline characteristics were comparable, except for higher chronic pulmonary disease prevalence (58.0% vs. 20.4%, P<0.001) and lower IL-6 levels (133.22 vs. 171.28, P<0.001) in the pt-qPCR group. Pathogen detection was significantly higher with pt-qPCR (94.4% vs. 53.6%, P<0.001). Compared to conventional testing, the pt-qPCR group showed reduced LOS (16 vs. 16 days, P=0.041), DOT (20 vs. 24 days, P=0.013), post-test antimicrobial use (8 vs. 12 days, P<0.001), and ICU transfer rate (31.5% vs. 49.2%, P=0.006). Mortality did not differ significantly between groups. The pt-qPCR group had a higher rate of antimicrobial regimen adjustment (34.3% vs. 19.6%, P=0.014) and fewer instances of escalation. A broader pathogen spectrum was detected using pt-qPCR, including 208 bacteria, 73 fungi, and 103 viruses, with 87 patients harboring multiple pathogens.Pharmacist-interpreted pt-qPCR significantly improves pathogen detection and optimizes antimicrobial therapy in LRTI patients. Its clinical use may enhance antibiotic stewardship, reduce ICU burden, and support precision medicine in respiratory infections.
Keywords: pt-qPCR, Antimicrobial stewardship, Lower respiratory tract infections, Rapid molecular diagnostics, Real-world study, Hospital-based study
Received: 30 Jun 2025; Accepted: 20 Aug 2025.
Copyright: © 2025 Wang, Wang, YAN, Wei, Yuan, Zhao, Liu, Yin and Yu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Wanyi Yin, The First hospital of Hebei Medical University, Shijiazhuang, China
Jing Yu, The First hospital of Hebei Medical University, Shijiazhuang, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.